Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $62.5 million.

  • Korro Bio's Total Liabilities fell 217.96% to $62.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.5 million, marking a year-over-year decrease of 217.96%. This contributed to the annual value of $65.8 million for FY2024, which is 2719.32% up from last year.
  • Per Korro Bio's latest filing, its Total Liabilities stood at $62.5 million for Q3 2025, which was down 217.96% from $65.3 million recorded in Q2 2025.
  • In the past 5 years, Korro Bio's Total Liabilities ranged from a high of $65.8 million in Q4 2024 and a low of $8.9 million during Q4 2022
  • For the 5-year period, Korro Bio's Total Liabilities averaged around $50.5 million, with its median value being $54.0 million (2022).
  • As far as peak fluctuations go, Korro Bio's Total Liabilities tumbled by 8366.16% in 2022, and later skyrocketed by 56490.84% in 2024.
  • Over the past 5 years, Korro Bio's Total Liabilities (Quarter) stood at $54.5 million in 2021, then crashed by 83.66% to $8.9 million in 2022, then skyrocketed by 480.83% to $51.8 million in 2023, then rose by 27.19% to $65.8 million in 2024, then fell by 5.02% to $62.5 million in 2025.
  • Its Total Liabilities stands at $62.5 million for Q3 2025, versus $65.3 million for Q2 2025 and $63.2 million for Q1 2025.